Immunologic enhancement with intermittent interleukin-2 therapy

Details Immunologic enhancement with intermittent interleukin-2 therapy Immunologic enhancement with intermittent interleukin-2 therapy

A - Human Necessities

61

K

A61K 38/20 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2163219

A method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For exemple, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

Affiliated with

Also associated with

Rating

Immunologic enhancement with intermittent interleukin-2 therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunologic enhancement with intermittent interleukin-2 therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunologic enhancement with intermittent interleukin-2 therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1762513